IE 11 is not supported. For an optimal experience visit our site on another browser.

Allos Therapeutics is's Biopharm Feature Stock

/ Source: GlobeNewswire

DALLAS, June 17, 2011 (GLOBE NEWSWIRE) -- announces an investment report featuring biopharmaceutical stock Allos Therapeutics Inc. (Nasdaq:ALTH). The report includes the most recent data from the company's peripheral T-cell lymphoma treatment study, as well as the Company's financial position, investment analyses, and industry information you need to know to make an educated investment decision.

The full report is available at:

Allos Therapeutics Inc. (ALTH) is a biopharmaceutical company engaged in the development and commercialization of anti-cancer therapeutics. The Company is focused on the development and commercialization of FOLOTYN (pralatrexate injection), a targeted antifolate inhibitor designed to accumulate preferentially in cancer cells.

This newsletter has been helping traders make great investment decisions on ALTH; click here for a 25% discount offer.

In the report, the analyst notes:

"Shares of ALTH spiked more than 8% Thursday after the cancer drug maker presented data from COMPLETE, an international registry designed to address the urgent need for an increased understanding of the treatment patterns and outcomes for patients with peripheral T-cell lymphoma (PTCL)."

"It is unique in that it is the first registry designed to characterize treatment patterns across practice settings in the United States and Europe for patients with PTCL, said Charles Morris MB ChB, MRCP, chief medical officer at ALTH."

To read the entire report visit:

See what investors are saying about ALTH at

Get breaking news on ALTH at is a small-cap research and investment commentary provider. strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on MicroStockProfit please visit: Disclosure is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. is a Web site wholly owned by BlueWave Advisors, LLC. Neither nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site,, for complete risks and disclosures.

CONTACT: Jay Geller 1-888-307-2850